Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)

Richard T Maziarz,Mrinal M Patnaik,Bart L Scott,Sanjay R Mohan,Abhinav Deol,Scott D Rowley,Dennis Dong Hwan Kim,Kelly Haines,Gaetano Bonifacio,Patrice Rine,Hugo F Fernandez

doi:10.1182/blood.v128.22.2248.2248

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)

Richard T Maziarz, Mrinal M Patnaik + Show 9 more

https://doi.org/10.1182/blood.v128.22.2248.2248

Copy DOI

Export

Save

Cite

Journal: Blood	Publication Date: Dec 2, 2016
Citations: 19

Affiliation: Oregon Health & Science University, Mayo Clinic, Fred Hutch Cancer Center, Vanderbilt University Medical Center, Karmanos Cancer Institute, Hackensack University Medical Center, Princess Margaret Cancer Centre, Tris Pharma (United States), Moffitt Cancer Center

#Standard Of Care Arm #Advisory Committees #Entity's Board #Standard Of Care #Acute Myeloid Leukemia #Board Of Directors #Speakers Bureau #Research Funding #Abnormal Test Results #FLT3-mutated Acute Myeloid Leukemia

Abstract
Full-Text
Similar Papers

Abstract

Listen

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)